Literature DB >> 2998804

Partial purification and biological properties of an eosinophil-activating factor.

K J Thorne, B A Richardson, M C Veith, P C Tai, C J Spry, A E Butterworth.   

Abstract

A protein (eosinophil-activating factor, EAF), which enhances the capacity of human peripheral blood eosinophils to kill antibody-coated schistosomula of Schistosoma mansoni, has been partially purified from supernatants of cultured peripheral blood mononuclear cells by sequential chromatography on Sephacryl S200 and DEAE-cellulose. This protein is acidic with a molecular mass on gel filtration of 40 +/- 7 kDa. It not only enhances the activity of eosinophils against schistosomula but also increases their ability to lyse antibody-coated, herpes simplex virus-infected Chang liver cells. It enhances the production of superoxide and hydrogen peroxide by eosinophils that occurs both spontaneously and in response to opsonized zymosan. However, increased respiratory burst activity does not appear to be responsible for the enhancement of eosinophil-mediated killing of schistosomula, since a comparable or greater increase in hydrogen peroxide production is induced by column fractions that have little or no effect on schistosomulum killing. EAF enhances eosinophil degranulation, both spontaneously and after incubation with opsonized zymosan. Enhanced degranulation is associated with release of eosinophil peroxidase and eosinophil cationic protein. These findings suggest that EAF enhances the capacity of eosinophils to kill parasites by increasing the extent of eosinophil degranulation and the amount of toxic granule proteins that are secreted.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998804     DOI: 10.1002/eji.1830151104

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Schistosome vaccines.

Authors:  D W Taylor
Journal:  Experientia       Date:  1991-02-15

Review 2.  Eosinophils. Assays and interpretation.

Authors:  D E Maddox
Journal:  Clin Rev Allergy       Date:  1988

3.  The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils.

Authors:  P C Tai; C J Spry
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

Review 4.  Eosinophils in eosinophilic endomyocardial disease.

Authors:  C J Spry
Journal:  Postgrad Med J       Date:  1986-06       Impact factor: 2.401

5.  The effects of eosinophil activating factor on IgG-dependent sulphidopeptide leukotriene generation by human eosinophils.

Authors:  P Fitzharris; R Moqbel; K J Thorne; B A Richardson; A Hartnell; O Cromwell; A E Butterworth; A B Kay
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

6.  Eosinophil-activating factor (EAF) production by a human cell line (ESH 98) stimulated with tumour necrosis factor.

Authors:  K J Thorne; B A Richardson; A E Butterworth; M Stanley
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

Review 7.  Endobiogeny: a global approach to systems biology (part 2 of 2).

Authors:  Jean-Claude Lapraz; Kamyar M Hedayat; Patrice Pauly
Journal:  Glob Adv Health Med       Date:  2013-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.